To validate the interaction observation under infection conditions, we infected the human lung carcinoma cell-line, A549, with PIV5 at a multiplicity of infection (MOI) of 2 PFU/cell, and 24 hours later prepared total soluble cell lysates for co-IP studies using an anti-TRIM28 antibody and an anti-V5 antibody, which targets a common epitope on both the PIV5 V and P proteins. This evidence concerns the gene TRIM28 and lung carcinoma.